Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

D. Shevrin · SciRah

Researcher profile · Semantic Scholar

D. Shevrin

Share profile

D. Shevrin — researcher profile on SciRah

h-index: 28
Works: 120
Citations: 6,259

Most-cited papers

Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer
C. Sweeney, Yu-Hui Chen, M. Carducci, Glenn Liu +13 more
2015New England Journal of Medicine2,654 citations Open access
Semantic Scholar
Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer: Long-Term Survival Analysis of the Randomized Phase III E3805 CHAARTED Trial.
Christos E. Kyriakopoulos, Yu-Hui Chen, M. Carducci, Glenn Liu +14 more
2018Journal of Clinical Oncology941 citations Open access
Semantic Scholar
Germline Mutations in ATM and BRCA1/2 Distinguish Risk for Lethal and Indolent Prostate Cancer and are Associated with Early Age at Death
R. Na, S. Zheng, Misop Han, Hong-Jie Yu +33 more
2016European Urology340 citations Open access
Semantic Scholar
Impact on overall survival (OS) with chemohormonal therapy versus hormonal therapy for hormone-sensitive newly metastatic prostate cancer (mPrCa): An ECOG-led phase III randomized trial.
C. Sweeney, Yu-Hui Chen, M. Carducci, Glenn Liu +13 more
2014Journal of Clinical Oncology202 citations
Semantic Scholar
Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012.
M. Hussain, S. Daignault-Newton, P. Twardowski, C. Albany +21 more
2017Journal of Clinical Oncology187 citations Open access
Semantic Scholar
Use of a single-item screening tool to detect clinically significant fatigue, pain, distress, and anorexia in ambulatory cancer practice.
Zeeshan Butt, L. Wagner, J. Beaumont, J. Paice +7 more
2008Journal of Pain and Symptom Management174 citations Open access
Semantic Scholar
Seven-Month Prostate-Specific Antigen Is Prognostic in Metastatic Hormone-Sensitive Prostate Cancer Treated With Androgen Deprivation With or Without Docetaxel.
L. Harshman, Yu-Hui Chen, Glenn Liu, M. Carducci +14 more
2017Journal of Clinical Oncology125 citations Open access
Semantic Scholar
The systemic delivery of an oncolytic adenovirus expressing decorin inhibits bone metastasis in a mouse model of human prostate cancer
Wei-Dong Xu, T. Neill, Yue-Feng Yang, Ze-Bin Hu +10 more
2014Gene Therapy93 citations Open access
Semantic Scholar
An item bank was created to improve the measurement of cancer-related fatigue.
J. Lai, D. Cella, K. Dineen, R. Bode +3 more
2005Journal of Clinical Epidemiology81 citations
Semantic Scholar
Long term efficacy and QOL data of chemohormonal therapy (C-HT) in low and high volume hormone naïve metastatic prostate cancer (PrCa): E3805 CHAARTED trial
C. Sweeney, Yu-Hui Chen, Glenn Liu, M. Carducci +14 more
201665 citations Open access
Semantic Scholar
Randomized, Double-Blinded Phase II Evaluation of Docetaxel with or without Doxercalciferol in Patients with Metastatic, Androgen-Independent Prostate Cancer
S. Attia, J. Eickhoff, G. Wilding, D. McNeel +12 more
2008Clinical Cancer Research53 citations Open access
Semantic Scholar
Background and Update for ECOG-ACRIN EA8212: A Randomized Phase 3 Trial of Intravesical Bacillus Calmette-Guérin (BCG) Versus Intravesical Docetaxel and Gemcitabine Treatment in BCG-naïve High-grade Non–muscle-invasive Bladder Cancer (BRIDGE)
M. Kates, X. Chu, N. Hahn, E. Pietzak +10 more
2023European Urology Focus51 citations Open access
Semantic Scholar
Radium-223 in combination with docetaxel in patients with castration-resistant prostate cancer and bone metastases: a phase 1 dose escalation/randomised phase 2a trial
M. Morris, Y. Loriot, C. Sweeney, K. Fizazi +11 more
2019European Journal of Cancer50 citations Open access
Semantic Scholar
Real-time clinical application of quality-of-life assessment in advanced lung cancer.
Chih-Hung Chang, D. Cella, G. Masters, Nicole Laliberté +3 more
2002Clinical Lung Cancer44 citations
Semantic Scholar
Constructing a conceptual framework of patient-reported outcomes for metastatic hormone-refractory prostate cancer.
D. Eton, D. Shevrin, J. Beaumont, David E Victorson +1 more
2010Value in Health42 citations Open access
Semantic Scholar
Safety, efficacy, and pharmacodynamics of the investigational agent orteronel (TAK-700) in metastatic castration-resistant prostate cancer (mCRPC): Updated data from a phase I/II study.
D. Agus, W. Stadler, D. Shevrin, L. Hart +8 more
2011Journal of Clinical Oncology40 citations
Semantic Scholar
Phase I/II Trial of Orteronel (TAK-700)—an Investigational 17,20-Lyase Inhibitor—in Patients with Metastatic Castration-Resistant Prostate Cancer
R. Dreicer, D. Maclean, A. Suri, W. Stadler +9 more
2014Clinical Cancer Research39 citations Open access
Semantic Scholar
Phase II Trial of Carboplatin, Everolimus, and Prednisone in Metastatic Castration-resistant Prostate Cancer Pretreated With Docetaxel Chemotherapy: A Prostate Cancer Clinical Trial Consortium Study
U. Vaishampayan, D. Shevrin, M. Stein, L. Heilbrun +7 more
2015Urology38 citations Open access
Semantic Scholar
A phase II study of continuous infusion 5‐fluorouracil in advanced hormone refractory prostate cancer. An illinois cancer center study
T. Kuzel, M. Tallman, D. Shevrin, E. Braud +6 more
1993Cancer38 citations
Semantic Scholar
PRESTO: A Phase Ill, Open-Label Study of Intensification of Androgen Blockade in Patients With High-Risk Biochemically Relapsed Castration-Sensitive Prostate Cancer (AFT-19)
R. Aggarwal, G. Heller, D. Hillman, Han Xiao +20 more
2024Journal of Clinical Oncology35 citations
Semantic Scholar
Efficient assessment of the most important symptoms in advanced prostate cancer: the NCCN/FACT‐P Symptom Index
David E Victorson, J. Beaumont, Sarah K. Rosenbloom, D. Shevrin +1 more
2011Psycho-Oncology34 citations
Semantic Scholar
Phase I/II trial of enzalutamide and mifepristone, a glucocorticoid receptor antagonist, for metastatic castration-resistant prostate cancer
Anthony V. Serritella, D. Shevrin, E. Heath, J. Wade +7 more
2022Clinical Cancer Research31 citations Open access
Semantic Scholar
Longitudinal screening and management of fatigue, pain, and emotional distress associated with cancer therapy
Zeeshan Butt, L. Wagner, J. Beaumont, J. Paice +6 more
2008Supportive Care in Cancer30 citations
Semantic Scholar
Abiraterone + prednisone (Abi) +/- veliparib (Vel) for patients (pts) with metastatic castration-resistant prostate cancer (CRPC): NCI 9012 updated clinical and genomics data.
M. Hussain, S. Daignault, P. Twardowski, C. Albany +16 more
201723 citations
Semantic Scholar
A randomized phase II study of pazopanib in hormone sensitive prostate cancer: a University of Chicago Phase II Consortium/ Department of Defense Prostate Cancer Clinical Trials Consortium study
J. E. Ward, T. Karrison, G. Chatta, M. Hussain +5 more
2011Prostate Cancer and Prostatic Diseases23 citations Open access
Semantic Scholar
Effects of radium-223 dichloride (Ra-223) with docetaxel (D) versus D on prostate-specific antigen (PSA) and bone alkaline phosphatase (bALP) in patients (pts) with castration-resistant prostate cancer (CRPC) and bone metastases (mets): A phase 1/2a clinical trial.
M. Morris, C. Higano, H. Scher, C. Sweeney +11 more
201520 citations
Semantic Scholar
Effect of etidronate disodium on the development of bone lesions in an animal model of bone metastasis using the human prostate cancer cell line PC‐3
D. Shevrin, Kathleen I. Gorny, Thomas J. Rosol, S. Kukreja
1991The Prostate19 citations
Semantic Scholar
Safety, efficacy, and pharmacodynamics of the investigational agent TAK-700 in metastatic castration-resistant prostate cancer (mCRPC): Updated data from a phase I/II study.
D. Agus, W. Stadler, D. Shevrin, L. Hart +8 more
2011Journal of Clinical Oncology18 citations
Semantic Scholar
Prolongation of Off-Cycle Interval by Finasteride Is Not Associated with Survival Improvement in Intermittent Androgen Deprivation Therapy in LNCaP Tumor Model
Yujuan Wang, Shubham Gupta, V. N. Hua, R. Ramos-Garcia +4 more
2009The Prostate18 citations Open access
Semantic Scholar
Updated results: A phase I/IIa randomized trial of radium-223 + docetaxel versus docetaxel in patients with castration-resistant prostate cancer and bone metastases.
M. Morris, Y. Loriot, C. Sweeney, K. Fizazi +7 more
201617 citations
Semantic Scholar
Randomized Phase 2 Trial of Abiraterone Acetate Plus Prednisone, Degarelix, or the Combination in Men with Biochemically Recurrent Prostate Cancer After Radical Prostatectomy
K. Autio, E. Antonarakis, T. Mayer, D. Shevrin +23 more
2021European Urology Open Science16 citations Open access
Semantic Scholar
Co-targeting androgen receptor (AR) and DNA repair: A randomized ETS gene fusion-stratified trial of abiraterone + prednisone (Abi) +/- the PARP1 inhibitor veliparib for metastatic castration-resistant prostate cancer (mCRPC) patients (pts) (NCI9012)--A University of Chicago phase II consortium tria
M. Hussain, S. Daignault, P. Twardowski, C. Albany +16 more
201616 citations
Semantic Scholar
Expansion of a physical function item bank and development of an abbreviated form for clinical research.
R. Bode, J. Lai, K. Dineen, A. Heinemann +3 more
2006Journal of Applied Measurement16 citations
Semantic Scholar
Use of Clonidine to Treat Hot Flashes Secondary to Leuprolide or Goserelin
L. Bressler, C. Murphy, D. Shevrin, R. Warren
1993The Annals of Pharmacotherapy15 citations
Semantic Scholar
Correlates of thrombin generation in patients with advanced prostate cancer
S. E. Lind, J. Caprini, Sofia Goldshteyn, J. Dohnal +2 more
2003Thrombosis and Haemostasis14 citations
Semantic Scholar
Inhibition of 5α-Reductase Enhances Testosterone-Induced Expression of U19/Eaf2 Tumor Suppressor During the Regrowth of LNCaP Xenograft Tumor in Nude Mice
Shubham Gupta, Yujuan Wang, R. Ramos-Garcia, D. Shevrin +2 more
2010The Prostate13 citations Open access
Semantic Scholar
Phase II trial of Echinomycin in advanced hormone-resistant prostate cancer
D. Shevrin, T. Lad, P. Guinan, L. Kilton +4 more
2004Investigational new drugs13 citations
Semantic Scholar
In vivo andin vitro approaches to study metastasis in human prostatic cancer
Chung Lee, D. Shevrin, J. Kozlowski
1993Cancer Metastasis Review13 citations
Semantic Scholar
Eight-year survival rates by baseline prognostic groups in patients with metastatic hormone-sensitive prostate cancer (mHSPC): An analysis from the ECOG-ACRIN 3805 (CHAARTED) trial.
Abhishek Tripathi, Yu-Hui Chen, D. Jarrard, N. Hahn +14 more
2022Journal of Clinical Oncology11 citations
Semantic Scholar
5α-reductase inhibition suppresses testosterone-induced initial regrowth of regressed xenograft prostate tumors in animal models.
K. Z. Masoodi, Raquel Ramos Garcia, L. E. Pascal, Yujuan Wang +9 more
2013Endocrinology11 citations Open access
Semantic Scholar
Association Between Baseline Body Mass Index and Survival in Men with Metastatic Hormone Sensitive Prostate Cancer: ECOG-ACRIN CHAARTED E3805
A. Morgans, Yu-Hui Chen, D. Jarrard, M. Carducci +13 more
2022The Prostate10 citations Open access
Semantic Scholar
Assessment of coagulation system activation using spot urine measurements.
S. E. Lind, Sofia Goldshteyn, Catherine P. Barry, J. R. Lindquist +5 more
1999Blood Coagulation and Fibrinolysis10 citations
Semantic Scholar
Effects of radium-223 (Ra-223) with docetaxel versus docetaxel alone on bone biomarkers in patients with bone-metastatic castration-resistant prostate cancer (CRPC): A phase I/IIa clinical trial.
M. Morris, Y. Loriot, K. Fizazi, C. Sweeney +6 more
20179 citations
Semantic Scholar
Genomic predictors for treatment of late stage prostate cancer
D. Shevrin
2016Asian Journal of Andrology9 citations Open access
Semantic Scholar
A case of therapy-related extramedullary acute promyelocytic leukemia.
Zhong Chen, Hassan Mostafavi, D. Shevrin, Rodman Morgan +3 more
1996Cancer Genetics and Cytogenetics9 citations
Semantic Scholar
Treatment registry for outcomes in patients with castration-resistant prostate cancer (TRUMPET): a methodology for real-world evidence and research
D. Penson, D. Lin, L. Karsh, D. Quinn +7 more
2016Future Oncology7 citations Open access
Semantic Scholar
Phase II trial of echinomycin in advanced hormone-resistant prostate cancer. An Illinois Cancer Council study.
D. Shevrin, T. Lad, P. Guinan, L. Kilton +4 more
1994Investigational new drugs7 citations
Semantic Scholar
765PDSAFETY OF RADIUM-223 DICHLORIDE (RA) WITH DOCETAXEL (D) IN PATIENTS (PTS) WITH BONE METASTASES (METS) FROM CASTRATION-RESISTANT PROSTATE CANCER (CRPC): A PHASE 1/2A CLINICAL TRIAL.
M. Morris, C. Higano, H. Scher, Christopher Sweeney +11 more
2014Annals of Oncology6 citations Open access
Semantic Scholar
5α-reductase Inhibition Coupled with Short Off Cycles Increases Survival in the LNCaP Xenograft Prostate Tumor Model on Intermittent Androgen Deprivation Therapy
L. E. Pascal, K. Z. Masoodi, Katherine J. O’Malley, D. Shevrin +3 more
2014Journal of Urology6 citations Open access
Semantic Scholar
314 ACTIVE TRIACYLGLYCEROL METABOLISM AND INCREASED INFILTRATING ADIPOCYTE DENSITY IN HIGH GRADE PROSTATE CANCER
Kristian R. Novakovic, Philip Fitchev, C. Brendler, B. Plunkett +7 more
20126 citations
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

M. Hussain×11
Invite
M. Hussain — researcher profile on SciRah
R. Dreicer×10
Invite
R. Dreicer — researcher profile on SciRah
M. Carducci×9
Invite
M. Carducci — researcher profile on SciRah
E. Antonarakis×9
Invite
E. Antonarakis — researcher profile on SciRah

×8

Invite

C. Sweeney — researcher profile on SciRah

Invite

Glenn Liu — researcher profile on SciRah

Invite

J. Picus — researcher profile on SciRah

Invite

W. Stadler — researcher profile on SciRah

Invite

D. Cella — researcher profile on SciRah

Invite

Yu-Hui Chen — researcher profile on SciRah

Invite

N. Hahn — researcher profile on SciRah

N. Vogelzang×7

Invite

N. Vogelzang — researcher profile on SciRah